Oramed Pharmaceuticals Inc. announced detailed results from its previously completed Phase 2a trial investigating ORMD-0801, its orally ingestible insulin capsule, in type 2 diabetes patients. The preliminary results of this trial were originally announced on Jan. 30, 2014

Read more